Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans. Celixir is a British biotechnology company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir’s unique, world-class technology platform drives in-house discovery and has created a pipeline of 20 tissue-specific regenerative medicines, an unprecedented feat in the field of regenerative medicine.
Celixir’s pipeline is led by their investigational cardiac regenerative medicine, HeartcelTM which is designed to treat patients with ischaemic heart disease undergoing coronary artery bypass graft. Alongside HeartcelTM, Celixir has late-stage development medicines in orthopaedics and mild to moderate heart failure as well as early phase development medicines in type 1 diabetes and oncology.
Ajan previously served as the Global Head of Emerging Technologies at Roche where he oversaw the identification, acquisition and development of the next generation of breakthrough biopharma technologies and products. He joined Roche as a Business Development Director for Roche Pharma, where he led merger & acquisitions teams and major licensing transactions. He is a former Boston Consulting Group Consultant. Ajan was awarded the Fulbright Scholar, an MBA from Kellogg Business school and studied Experimental Therapeutics (MSC) at the University of Oxford.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.